Medical devices, healthcare technology and the business of care
PMA approval · P160043

RESOLUTE ONYX ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

Medtronic Vascular · Decision date Apr 28, 2017

MEDTECHLEDGER EXPLANATIONP160043

What did the FDA approve?

FDA approved PMA P160043 for the Resolute Onyx Zotarolimus-Eluting Coronary Stent System on April 28, 2017. The applicant is Medtronic Vascular, and the product code is NIQ under the cardiovascular specialty.

The approval statement describes the device as indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length less than or equal to 35 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 5.0 mm. The record does not include supplement type or supplement reason fields.

FDA approval order statement

Approval for the Resolute Onyx Zotarolimus-Eluting Coronary Stent System. This device is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length less than or equal to 35 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 5.0 mm.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Apr 28, 2017

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P160043
Regulatory pathway
Premarket approval application
Product code
NIQ
Decision code
APPR
Decision date
Apr 28, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Product code
NIQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P160043 received

    Application receipt date recorded by FDA.

  2. P160043 · FDA decision

    APPR

  3. P160043/S096 · Related supplement

    Resolute Onyx Zotarolimus-Eluting Coronary Stent Systems

Timeline entries are records held by MedtechLedger for P160043. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160043

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic VascularPMA supplementOct 16, 2026FDA

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Vascular

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3576 Unocal Pl., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records